Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai's Newly Acquired Lorcaserin Faced With Regulatory Hurdle After Qnexa Advisory Committee Vote

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Weeks after securing U.S. rights for the first of three much-touted obesity drugs, Eisai and partner Arena now face an unsure future for lorcaserin after a U.S. FDA advisory committee voted against recommending approval for Vivus' Qnexa based on safety concerns
Advertisement

Related Content

Eisai Seeks Lunesta Approval In Japan After Phase III Data, But Disease Awareness Is A Challenge
Eisai Seeks Lunesta Approval In Japan After Phase III Data, But Disease Awareness Is A Challenge
Qnexa May Get Staged Launch After No Vote From Advisory Committee
Qnexa Proposed REMS Focuses On Registry, Web-Based Physician Education
Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
Advertisement
UsernamePublicRestriction

Register

SC075427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel